RA
DSCI

Royce & Associates’s Derma Sciences, Inc. Common Stock (DE) DSCI Stock Holding History

Royce & Associates’s Portfolio DSCI Stock Details DSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-549,341
Closed -$2.86M – 1164
2016
Q4 		$2.86M Buy
549,341
+216,820
+65% +$1.02M 0.02% 728
2016
Q3 		$1.55M Buy
332,521
+100,000
+43% +$467K 0.01% 857
2016
Q2 		$916K Sell
232,521
-4,986
-2% -$18.6K 0.01% 930
2016
Q1 		$736K Hold
237,507
– – ﹤0.01% 957
2015
Q4 		$1.08M Buy
237,507
+16,000
+7% +$75.9K 0.01% 926
2015
Q3 		$1.04M Sell
221,507
-170,993
-44% -$1.1M 0.01% 961
2015
Q2 		$2.81M Buy
392,500
+49,900
+15% +$375K 0.01% 869
2015
Q1 		$2.9M Buy
342,600
+180,500
+111% +$1.54M 0.01% 864
2014
Q4 		$1.51M Buy
162,100
+107,100
+195% +$931K 0.01% 1021
2014
Q3 		$458K Hold
55,000
– – ﹤0.01% 1216
2014
Q2 		$636K Hold
55,000
– – ﹤0.01% 1202
2014
Q1 		$697K Hold
55,000
– – ﹤0.01% 1190
2013
Q4 		$595K Buy
+55,000
New +$639K ﹤0.01% 1223

Other funds holding DSCI

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Royce & Associates's DSCI Position: Q1 2017 in Review

Royce & Associates sold out of Derma Sciences, Inc. Common Stock (DE) (DSCI) in Q1 2017, closing a stake of 549,341 shares — an estimated $2.86M sold.

Royce & Associates first reported a position in DSCI in Q4 2013 and held it in 13 quarters. The position peaked at $2.9M in Q1 2015. 1 fund tracked by Wall St. Rank holds DSCI as of Q1 2017.

  • Royce & Associates reported no remaining Derma Sciences, Inc. Common Stock (DE) position as of Q1 2017 after selling out during the quarter.
  • Royce & Associates sold 549,341 Derma Sciences, Inc. Common Stock (DE) shares in Q1 2017, an estimated $2.86M.
  • Royce & Associates first reported a position in Derma Sciences, Inc. Common Stock (DE) in Q4 2013 and held it in 13 quarters.
  • Royce & Associates's Derma Sciences, Inc. Common Stock (DE) position peaked at $2.9M in Q1 2015.
  • 1 fund tracked by Wall St. Rank held Derma Sciences, Inc. Common Stock (DE) as of Q1 2017.

Based on Royce & Associates's 13F filing for Q1 2017, filed 11 May 2017.